1994

FDA Approves First U.S. HIV Test System Using Oral Fluid Samples
Food and Drug Administration, U.S. Department of Health and Human Services - December 23, 1994
The Food and Drug Administration today announced that it has approved the first U.S. HIV test system using oral fluid samples. Until now, all approved HIV tests have used blood samples. In approving this new HIV test system, FDA approved both a product for collecting specimens of oral fluid and a specific test used to


The FDA Approves Silicone Oil, A New Product for Reattaching the Retina
Food and Drug Administration
Sharon Snider (301) 443-3285
The FDA today announced approval of silicone oil, a new product for reattaching the retina in certain complicated cases of retinal detachment. The retina can become detached from within the eye through injury or disease, including AIDS. If untreated, this can result in blindness. In clinical studies of patients with c


FDA today announced the approval of stavudine, or D4T
Food and Drug Administration
Arthur Whitmore (301) 443-3285
The Food and Drug Administration today announced the approval of stavudine, or D4T -- the fourth drug approved for the treatment of AIDS and HIV infection. Stavudine is an antiviral agent of the nucleoside analog class, which includes zidovudine ( AZT ), didanosine


MEDIA ADVISORY: Task Force On AIDS Drug Development To Meet
Food and Drug Administration, April 13, 1994
Arthur Whitmore (301) 443-4177
The National Task Force on AIDS Drug Development will meet Thursday and Friday, April 14 and 15, at the Sheraton National Hotel, Columbia Pike and Washington Boulevard, Arlington, Va. The meeting will be from 8:30 a.m. to 5:30 p.m. on Thursday and from 8:30 a.m. to 11:30 a.m. on Friday. Secretary of Health and Human Se


FDA Approved 370 New Drug, Generic Drug and Biological Product Applications in 1993
Food and Drug Administration, January 13, 1994
Mike Shaffer (301) 443-3285
FDA approved 370 new drug, generic drug and biological product applications in 1993. Seventy of the approvals were for new drugs, 51 were for biological products and 249 were for generic versions of new drugs. Twenty-five of the new drug approvals are for new molecular entities (NMEs) -- drugs distinctly different in



This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 1994. AEGiS.